Quick profiles: Emma Hilton

Emma is now Global Medical Affairs Leader for Chronic Obstructive Pulmonary Disease (COPD) in GSK’s Respiratory Division. Read more
Emma is now Global Medical Affairs Leader for Chronic Obstructive Pulmonary Disease (COPD) in GSK’s Respiratory Division. Read more
Alzheimer’s disease (AD) is a devastating neurodegenerative disease that could become an even more massive public health problem than it already is, if current projections hold. Some predict that by 2050, 1 in 85 individuals will be affected by the disease. Currently, there is no cure, but there are neurotransmitter-enhancement-based strategies to slow down the cognitive deficits [the loss of cholinergic neurons is implicated in some of the memory problems associated with AD so therefore, pharmacological enhancement of brain acetylcholine concentration can partially alleviate some memory-based symptoms.] However, as with many neurodegenerative diseases, these stop-gap treatments only work for so long, until the cells responding to neurotransmitter supplementation treatments die off completely. Therefore, diverse strategies designed to cure or at least slow down AD are imperative. Read more